Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
Open accessThe DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
OverviewDNA damaging chemotherapy is the first line of treatment for certain cancers, but its longterm success is often marred by the eventual acquisition of chemoresistance.Other cancers cannot be treated because they are intrinsically resistant to such chemotherapy.These 2 types of resistance are coupled in the context of translesion synthesis (TLS), which is carried out by specialized TLS DNA polymerases that can replicate past DNA lesions but in a lower fidelity manner.First, TLS DNA polymerases permit the bypass of modified DNA bases during DNA synthesis, thereby allowing proliferation to continue in the presence of chemotherapy, an issue of particular relevance to intrinsic drug resistance.Second, mistakes introduced by TLS polymerases copying over DNA lesions introduced during the chemotherapy lead to mutations that contribute to acquired resistance.These dual functions of mutagenic TLS polymerases with respect to chemoresistance make these proteins very promising targets for adjuvant therapy.The major branch of mutagenic TLS requires REV1, a Y family DNA polymerase that recruits other TLS polymerases with its C-terminal domain (CTD) including POL z, which is also required.Recent evidence obtained using mouse models is summarized, which shows that interfering with REV1/POL z-dependent mutagenic TLS during DNA damaging chemotherapy can help overcome problems due to both intrinsic resistance and acquired resistance.Ways to develop drugs that block mutagenic TLS are also considered, including taking advantage of structural knowledge to target key protein-protein interfaces.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because TLS events may protect tumor cells by favoring DNA replication”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [108]
In the citing paper
“TLS is considered a potential target in cancer therapy [98,108,109]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [108]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krokan, H. E., & Bjoras, M. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012583 · Cited by 1,322
The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase η
Masutani, C., Kusumoto, R., Yamada, A., Dohmae, N., Yokoi, M., Yuasa, M., Araki, M., Iwai, S., Takio, K., & Hanaoka, F. (1999) · Nature · doi:10.1038/21447 · Cited by 1,292 · cited 3×
“Pamoic acid, aurintricarboxylic acid, and ellagic acid were found to inhibit POL ι and POL η [112], while candesartan cilexetil inhibited the enzymatic function of POL κ as well as enhanced UV-induced cytotoxicity in xeroderma pigmentosum-variant (XP-V) cells [116].”
BackgroundInfluentialNucleotide Excision Repair in Eukaryotes
Scharer, O. D. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012609 · Cited by 801
Stromal biology and therapy in pancreatic cancer
Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., et al. (2011) · Gut · doi:10.1136/gut.2010.226092 · Cited by 757 · cited 1×
“Many tumors, including most pancreatic adenocarcinomas, nonsmall cell lung cancers, and aggressive brain tumors, as well as most metastatic malignancies, fail to significantly regress following chemotherapy [2].”
BackgroundInfluentialY-family DNA polymerases and their role in tolerance of cellular DNA damage
Sale, J. E., Lehmann, A. R., & Woodgate, R. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3289 · Cited by 665 · cited 2×
“REV1 functions as a principle scaffolding protein, which recruits other TLS polymerases to first insert a nucleotide opposite the DNA lesion and then eventually help extend the distorted primer-template terminus, in what is recognized as the two-step mechanism of TLS (Fig 2) [7, 8, 89].”
BackgroundMechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660 · cited 1×
“This can include the activation of drug efflux pumps or detoxifying processes that effectively reduce intracellular drug concentration [1].”
BackgroundEukaryotic polymerases ι and ζ act sequentially to bypass DNA lesions
Johnson, R. E., Washington, M. T., Haracska, L., Prakash, S., & Prakash, L. (2000) · Nature · doi:10.1038/35023030 · Cited by 632 · cited 2×
“POL ζ4 B-family (REV3 [REV3] polymerase, REV7 [REV7], POLD2 and POLD3 accessory subunits) [65] • POL ζ4 mediate inefficient TLS across CPDs, (6–4) photoproducts, adducted residues and AP sites, but an error free bypass of thymine glycols [53, 66, 67] • Serves as the key extender polymerase during TLS [68] • REV3 prote…”
BackgroundREV7 counteracts DNA double-strand break resection and affects PARP inhibition
Xu, G., Chapman, J. R., Brandsma, I., Yuan, J., Mistrik, M., Bouwman, P., Bartkova, J., Gogola, E., Warmerdam, D., Barazas, M., et al. (2015) · Nature · doi:10.1038/nature14328 · Cited by 593
Eukaryotic Translesion Polymerases and Their Roles and Regulation in DNA Damage Tolerance
Waters, L. S., Minesinger, B. K., Wiltrout, M. E., D'Souza, S., Woodruff, R. V., & Walker, G. C. (2009) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00034-08 · Cited by 591 · cited 2×
“REV1 functions as a principle scaffolding protein, which recruits other TLS polymerases to first insert a nucleotide opposite the DNA lesion and then eventually help extend the distorted primer-template terminus, in what is recognized as the two-step mechanism of TLS (Fig 2) [7, 8, 89].”
BackgroundSelf-citationDeoxycytidyl transferase activity of yeast REV1 protein
Nelson, J. R., Lawrence, C. W., & Hinkle, D. C. (1996) · Nature · doi:10.1038/382729a0 · Cited by 572 · cited 1×
“REV1 (REV1) Y-family • Exclusively inserts dCMPs opposite template Gs, abasic sites, and adducted G residues [13, 14] • Acts as a scaffolding protein by interacting with both POL ζ and RIR containing POL η, POL κ and POL ι [15, 16] • Generates G/C substitutions during Ig gene somatic hypermutation [17] • Accumulates i…”
Background
Cited by
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
“DNA lesions, single strand breaks (SSB) and double strand breaks (DSB), are repaired by different DDR pathways including BER, NER, mismatch repair (MMR), homologous recombination (HR), non-homologous end joining (NHEJ), translesion synthesis (TLS) and Fanconi anemia (FA) pathway (Bellon et al., 1991; Tian et al., 2015…”
BackgroundDNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 446
A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy
Wojtaszek, J. L., Chatterjee, N., Najeeb, J., Ramos, A., Lee, M., Bian, K., Xue, J. Y., Fenton, B. A., Park, H., Li, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.028 · Cited by 194
Self-citationTaglialatela, A., Leuzzi, G., Sannino, V., Cuella-Martin, R., Huang, J.-W., Wu-Baer, F., Baer, R., Costanzo, V., & Ciccia, A. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.016 · Cited by 173
Leveraging the replication stress response to optimize cancer therapy
Cybulla, E., & Vindigni, A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00518-6 · Cited by 153
Jain, R., Aggarwal, A. K., & Rechkoblit, O. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2018.06.003 · Cited by 135
CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication
Mansilla, S. F., De La Vega, M. B., Calzetta, N. L., Siri, S. O., & Gottifredi, V. (2020) · Genes · doi:10.3390/genes11060593 · Cited by 114
DNA polymerase ζ in DNA replication and repair
Martin, S. K., & Wood, R. D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz705 · Cited by 122
“Another approach may be to target small-molecule inhibitors to the pol complex (122).”
BackgroundTo skip or not to skip: choosing repriming to tolerate DNA damage
Quinet, A., Tirman, S., Cybulla, E., Meroni, A., & Vindigni, A. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.012 · Cited by 130
“, 2018), paving the way to the proposal of inhibition of ssDNA gap filling by TLS as a novel strategy for targeted cancer therapy (Yamanaka et al., 2017).”
BackgroundŠevčíková, A., Izoldova, N., Števurková, V., Kasperova, B., Chovanec, M., Čierniková, S., & Mego, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010488 · Cited by 112
“On the other hand, the mechanism of mutagenic translesion synthesis allowed the tolerance of DNA damage after genotoxic chemotherapy [20,21].”
BackgroundChemical Insights into Oxidative and Nitrative Modifications of DNA
Andrés, C. M. C., de la Lastra, J. M. P., Andrés, C., Plou, F. J., & Pérez‐Lebeña, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015240 · Cited by 101
Link Between Antibiotic Persistence and Antibiotic Resistance in Bacterial Pathogens
Eisenreich, W., Rudel, T., Heesemann, J., & Goebel, W. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.900848 · Cited by 98
Structure and mechanism of B-family DNA polymerase ζ specialized for translesion DNA synthesis
Malik, R., Kopylov, M., Gómez-Llorente, Y., Jain, R., Johnson, R. E., Prakash, L., Prakash, S., Ubarretxena‐Belandia, I., & Aggarwal, A. K. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0476-7 · Cited by 72
Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer
Gąsiorkiewicz, B., Koczurkiewicz, P., Piska, K., & Pękala, E. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-01032-y · Cited by 65
SARS-CoV-2 triggers DNA damage response in Vero E6 cells
Victor, J., Deutsch, J., Whitaker, A., Lamkin, E. N., March, A., Zhou, P., Botten, J., & Chatterjee, N. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.024 · Cited by 59
Self-citationChatterjee, N., Whitman, M. A., Harris, C. A., Min, S. M., Jonas, O. H., Lien, E. C., Luengo, A., Heiden, M. G. V., Hong, J., Zhou, P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016064117 · Cited by 58
Self-citationPolymerase iota - an odd sibling among Y family polymerases
McIntyre, J. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102753 · Cited by 52
Filling gaps in translesion DNA synthesis in human cells
Quinet, A., Lerner, L. K., Martins, D. J., & Menck, C. F. M. (2018) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2018.02.004 · Cited by 48
Mammalian DNA Polymerase Kappa Activity and Specificity
Stern, H. R., Sefcikova, J., Chaparro, V. E., & Beuning, P. J. (2019) · Molecules · doi:10.3390/molecules24152805 · Cited by 46
Drug resistance: from bacteria to cancer
Patel, H. H., Wu, Z., Chen, Y., Bo, L., & Chen, Z. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00041-4 · Cited by 45
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy
Baillie, K. E., & Stirling, P. C. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.10.010 · Cited by 43
Szikriszt, B., Póti, Á., Németh, E., Kanu, N., Swanton, C., & Szüts, D. (2021) · Mutagenesis · doi:10.1093/mutage/geab005 · Cited by 44
“Platinum mutations are generated by translesion DNA synthesis, therefore inhibitors of translesion polymerases could potentially be used to limit the mutagenic effects of chemotherapies (64).”
BackgroundTranslesion synthesis inhibitors as a new class of cancer chemotherapeutics
Patel, S. M., Dash, R. C., & Hadden, M. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1850692 · Cited by 41
The Rev1-Polζ translesion synthesis mutasome: Structure, interactions and inhibition
Rizzo, A. A., & Korzhnev, D. M. (2019) · The Enzymes · doi:10.1016/bs.enz.2019.07.001 · Cited by 42
Regulation of translesion DNA synthesis in mammalian cells
Ma, X., Tang, T., & Guo, C. (2020) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22359 · Cited by 41
Barnes, R. P., Tsao, W.-C., Moldovan, G., & Eckert, K. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3931 · Cited by 39
Incomplete base excision repair contributes to cell death from antibiotics and other stresses
Gruber, C. C., & Walker, G. C. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.08.014 · Cited by 40
“DNA repair pathways are also currently being investigated as potential targets for adjuvants in chemotherapy [143] with APE itself being a promising target [144].”
BackgroundSelf-citationTargeting translesion synthesis (TLS) to expose replication gaps, a unique cancer vulnerability
Nayak, S. U., Calvo, J. A., & Cantor, S. B. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1864321 · Cited by 39
DNA Damage Tolerance Pathways in Human Cells: A Potential Therapeutic Target
Ler, A. A. L., & Carty, M. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.822500 · Cited by 42
Recent developments in photodynamic therapy and its application against multidrug resistant cancers
Bhattacharya, D., Mukhopadhyay, M., Shivam, K., Tripathy, S., Patra, R., & Pramanik, A. (2023) · Biomedical Materials · doi:10.1088/1748-605x/ad02d4 · Cited by 39
“Deregulated activity in DNA damage repair pathways and significantly enhanced capacity of the cell to restore DNA damage and prevent apoptosis is closely linked with the emergence of drug resistance [198].”
BackgroundTargeting protein–protein interactions in the DNA damage response pathways for cancer chemotherapy
McPherson, K. S., & Korzhnev, D. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00101a · Cited by 39
Poustforoosh, A., Faramarz, S., Negahdaripour, M., Tüzün, B., & Hashemipour, H. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2196347 · Cited by 33
“POLK is a DNA polymerase involved in the process of trans-lesion DNA synthesis (TLS) (Yamanaka et al., 2017).”
BackgroundVassel, F.-M., Bian, K., Walker, G. C., & Hemann, M. T. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016067117 · Cited by 32
Self-citationVillafañez, F., García, I. A., Carbajosa, S., Pansa, M. F., Mansilla, S., Llorens, M. C., Angiolini, V., Guantay, L., Jacobs, H., Madauss, K. P., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0724-7 · Cited by 30
“polymerases have been reported [11], we believe that inhibiting PCNA ubiquitylation should have a more robust effect on TLS inhibition, as it would have a universal effect on the recruitment of TLS polymerases.”
BackgroundSOS-independent bacterial DNA damage responses: diverse mechanisms, unifying function
Kamat, A., & Badrinarayanan, A. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2023.102323 · Cited by 33
“Apart from their impact on evolution, such inducible mutagenesis can lead to genetic defects and cancer in human cells as well as antibiotic and stress resistance in bacteria [10–12].”
The in vivo role of Rev1 in mutagenesis and carcinogenesis
Sasatani, M., Zaharieva, E. K., & Kamiya, K. (2020) · Genes and Environment · doi:10.1186/s41021-020-0148-1 · Cited by 29
REV1 promotes lung tumorigenesis by activating the Rad18/SERTAD2 axis
Chen, Y., Jie, X., Xing, B., Wu, Z., Yang, X., Rao, X., Xu, Y., Zhou, D., Dong, X., Zhang, T., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04567-5 · Cited by 26
“RESULTS REV1 is overexpressed and indicates poor prognosis in lung cancer TLS is an error-prone DNA damage tolerance mechanism that can increase both the frequency of mutations and tumorigenesis [22].”
BackgroundTargeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy
Nickoloff, J. A. (2022) · Molecules · doi:10.3390/molecules27154736 · Cited by 34
Catalytic and noncatalytic functions of DNA polymerase κ in translesion DNA synthesis
Sellés‐Baiget, S., Ambjørn, S. M., Carli, A., Hendriks, I. A., Gallina, I., Davey, N. E., Benedict, B., Zarantonello, A., Gadi, S. A., Meeusen, B., et al. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01395-3 · Cited by 21
“Emerging strategies in cancer therapy include the development of TLS inhibitors, which may enhance tumor sensitivity to first-line chemotherapeutics 75,76 .”
Limited DNA repair gene repertoire in Ascomycete yeast revealed by comparative genomics
Milo, S., Misgav, R. H., Hazkani‐Covo, E., & Covo, S. (2019) · Genome Biology and Evolution · doi:10.1093/gbe/evz242 · Cited by 20
REV1 Inhibition Enhances Radioresistance and Autophagy
Ikeh, K., Lamkin, E. N., Crompton, A., Deutsch, J., Fisher, K., Gray, M., Argyle, D. J., Lim, W. Y., Korzhnev, D. M., Hadden, M. K., et al. (2021) · Cancers · doi:10.3390/cancers13215290 · Cited by 19
“Previously, REV1 inhibitors that targeted specific interfaces of this CTD were shown to sensitize cancer cells to chemotherapy treatment, which suggested that the REV1-dependent DNA damage bypass of chemotherapy-induced damage was the cause of chemoresistance [2–5,8].”
Self-citationFork Protection and Therapy Resistance in Hereditary Breast Cancer
Cantor, S. B., & Calvo, J. A. (2017) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2017.82.034413 · Cited by 22
“Nevertheless, it is an important therapeutic target (Yamanaka et al. 2017) given the growing body of evidence illustrating a causative role for TLS in the development of chemoresistance (Doles et al.”
BackgroundREV1: A novel biomarker and potential therapeutic target for various cancers
Zhu, N., Zhao, Y., Mi, M., Lu, Y., Tan, Y., Fang, X., Weng, S., & Yuan, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.997970 · Cited by 18
“It recruits the TLS polymerases POL κ, POL ι, and POL η using one interface, and recruits POL ζ through interaction with REV7 components by another interface (Pozhidaeva et al., 2012; Wojtaszek et al., 2012; Yamanaka et al., 2017).”
BackgroundMethodTarantino, D., Walker, C., Weekes, D. B., Pemberton, H. N., Davidson, K., Torga, G., Frankum, J. R., Mendes‐Pereira, A. M., Prince, C., Ferro, R., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02369-9 · Cited by 17
Dash, R. C., Ozen, Z., McCarthy, K. R., Chatterjee, N., Harris, C. A., Rizzo, A. A., Walker, G. C., Korzhnev, D. M., & Hadden, M. K. (2019) · ChemMedChem · doi:10.1002/cmdc.201900307 · Cited by 15
Self-citationMenck, C. F. M., Galhardo, R. S., & Quinet, A. (2023) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2023.111840 · Cited by 16
Targeting proliferating cell nuclear antigen (PCNA) for cancer therapy
Søgaard, C. K., & Otterlei, M. (2024) · Advances in pharmacology · doi:10.1016/bs.apha.2024.04.002 · Cited by 16
Cryo-EM reveals conformational flexibility in apo DNA polymerase ζ
Truong, C. D., Craig, T. A., Cui, G., Botuyan, M. V., Serkasevich, R. A., Chan, K.-Y., Mer, G., Chiu, P., & Kumar, R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100912 · Cited by 13
“A future challenge will be to determine the structure of human Polζ, which would be of high value for the long-term development of new anticancer drugs (15, 17, 52, 53).”
BackgroundREV1-POL ζ Inhibition and Cancer Therapy
Taniguchi, T. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.012 · Cited by 12
Protein–Protein Interactions in Translesion Synthesis
Dash, R. C., & Hadden, M. K. (2021) · Molecules · doi:10.3390/molecules26185544 · Cited by 13
AlSaihati, H., & Rabaan, A. A. (2023) · Saudi Medical Journal · doi:10.15537/smj.2023.44.4.20220600 · Cited by 12
“Yamanaka et al 32 also discovered a link between the disruptive POL and better DNA-lesion chemotherapeutic effectiveness.”
BackgroundDisrupting the MAD2L2-Rev1 Complex Enhances Cell Death upon DNA Damage
Pernicone, N., Elias, M., Onn, I., Tobi, D., & Listovsky, T. (2022) · Molecules · doi:10.3390/molecules27030636 · Cited by 12
SARS-CoV-2 hijacks host cell genome instability pathwaysPreprint
Victor, J., Jordan, T. X., Lamkin, E. N., Ikeh, K., March, A., Frere, J. J., Crompton, A., Allen, L., Fanning, J. E., Lim, W. Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1556634/v1 · Cited by 12
Self-citationMaloisel, L., Ma, É., Phipps, J., Deshayes, A., Mattarocci, S., Marcand, S., Dubrana, K., & Coïc, E. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010639 · Cited by 12
Protein Assemblies in Translesion Synthesis
Arianna, G. A., & Korzhnev, D. M. (2024) · Genes · doi:10.3390/genes15070832 · Cited by 12
Potential New Therapeutic Approaches for Cisplatin-Resistant Testicular Germ Cell Tumors
Lengert, A. V. H., Pereira, L. D. N. B., Cabral, E. R. M., Gomes, I. N. F., de Jesus, L. M., Gonçalves, M. F. S., da Rocha, A. O., Tassinari, T. A., da Silva, L. S., Laus, A. C., et al. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2708245 · Cited by 11
“TLS has been associated with CDDP-resistance in other tumors with basically a dual role, suggesting that TLS inhibition may sensitize tumors to therapy as well as prevent the emergence of tumor chemoresistance [27,52].”
BackgroundMcPherson, K. S., Zaino, A. M., Dash, R. C., Rizzo, A. A., Li, Y., Hao, B., Bezsonova, I., Hadden, M. K., & Korzhnev, D. M. (2021) · ChemMedChem · doi:10.1002/cmdc.202000893 · Cited by 9
Munafò, F., Nigro, M., Brindani, N., Manigrasso, J., Geronimo, I. M., Ottonello, G., Armirotti, A., & Vivo, M. D. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115044 · Cited by 8
The Role of m6A-Mediated DNA Damage Repair in Tumor Development and Chemoradiotherapy Resistance
Qu, L., Liu, S. J., Zhang, L., Liu, J., Zhou, Y. J., Zeng, P. H., Jing, Q., & Yin, W. J. (2024) · Cancer Control · doi:10.1177/10732748241247170 · Cited by 13
“56 Mu-tagenic events induced by TLS polymerases can contribute to tumorigenesis36 and impact the response of cancer cells to DNA-damaging chemotherapies, 57 highlighting the importance of these mechanisms in the context of tumour treat-ment.”
BackgroundXPA tumor variant leads to defects in NER that sensitize cells to cisplatin
Blee, A. M., Gallagher, K., Kim, H.-S., Kim, M., Kharat, S. S., Troll, C. R., D’Souza, A., Park, J., Neufer, P. D., Schärer, O. D., et al. (2024) · NAR Cancer · doi:10.1093/narcan/zcae013 · Cited by 7
“( 6 ) However, cisplatin lesions are known to be repaired by additional pathways in cells including DSB repair and ICL repair ( 42 ) or overcome through translesion synthesis (TLS) ( 53 ).”
Ribeiro, D. L., Latância, M. T., de Souza, I., Ariwoola, A.-B. A., Mendes, D., Rocha, C. R. R., Lengert, A. V. H., & Menck, C. F. M. (2024) · Bioscience Reports · doi:10.1042/bsr20230667 · Cited by 6
“Furthermore, tumor cells exhibit heightened expression of DNA damage tolerance (DDT) mechanisms, enabling the cells to withstand the genomic lesions induced by chemotherapy agents [11,12].”
Degtyareva, N. P., Placentra, V. C., Gabel, S. A., Klimczak, L. J., Gordenin, D. A., Wagner, B. A., Buettner, G. R., Mueller, G. A., Smirnova, T. I., & Doetsch, P. W. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad305 · Cited by 6
Wang, Z. P., Chen, F., Wang, Y., & Gou, S. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116647 · Cited by 5
A stapled POL κ peptide targets REV1 to inhibit mutagenic translesion synthesis
Chatterjee, N., D’Souza, S., Mir, M. S., Harris, C. A., Hilinski, G. J., Verdine, G. L., & Walker, G. C. (2020) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22395 · Cited by 5
“Translesion synthesis is a DNA damage bypass process where a group of low fidelity polymerases come together to tolerate a DNA lesion (Yamanaka et al., 2017).”
BackgroundSelf-citationChen, F., Wen, X., Li, S., Wu, J., Luo, Y., Gao, Y., Yu, X., & Chen, L. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102350 · Cited by 3
“We have known that chemotherapy and γ -irradiation could trigger CIN, which is a maligant tumor hallmark associated with required resistance, immune evasion and tumor metastasis [38].”
Zaino, A. M., Dash, R. C., James, S. J., MacGilvary, N. J., Crompton, A., McPherson, K. S., Stanzione, M., Korzhnev, D. M., Dyson, N. J., Chatterjee, N., et al. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117755 · Cited by 3
Self-citationDNA polymerases as chemotherapy targets: promise and challenges
Eckert, K. A., & Barnes, R. P. (2019) · Oncotarget · doi:10.18632/oncotarget.26572 · Cited by 3
Reaction pathways and technologies of in vitro DNA synthesis
Zhou, H., Li, H., Jia, Z., Niu, S., & Song, Y. (2025) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.102777 · Cited by 2
REV1 Loss Triggers a G2/M Cell-Cycle Arrest Through Dysregulation of Mitotic Regulators
Buntin, B., Guyette, M., Gupta, V., Ikeh, K., Bhattacharya, S., Lamkin, E. N., Lafuze, A., del Río, R., Hong, J., Zhou, P., et al. (2025) · Genes · doi:10.3390/genes17010044 · Cited by 2
“Sometimes, this also helps cancer cells re-sist therapy by avoiding therapy-induced damage and escaping cell death [27–29].”
Self-citationREV1 inhibition enhances trinucleotide repeat mutagenesis
Siegel, A., Almstead, D., Kothandaraman, N., Reich, J., Lamkin, E. N., Victor, J., Grover, A., Ikeh, K., Koval, H., Crompton, A., et al. (2025) · Open Biology · doi:10.1098/rsob.250234 · Cited by 2
Self-citationDetermination of DNA lesion bypass using a ChIP-based assay
Wu, D., Banerjee, A. T., Cai, S., Li, N., Han, C., Bai, X., Zhang, J., & Wang, Q. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103230 · Cited by 2
Chen, F., Wang, Z. P., Wang, Y., & Gou, S.-H. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113774 · Cited by 2
Bian, K., Gruber, C. C., Byers, E., Leclerc, P., Hemann, M. T., & Walker, G. C. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2511136122 · Cited by 3
“…both eukaryotes and prokaryotes possess an extremely important mutagenic TLS pathway that not only promotes survival by allowing cells to complete a cycle of DNA replication after damage by copying over a wide variety of lesions but also introduces mutations during the process ( 1 , 2 , 8 , 9 ).”
Self-citationSharma, A., Das, A., Bal, A., Srinivasan, R., Malhotra, P., Prakash, G., & Kumar, R. (2023) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001168 · Cited by 1
“14 Hence a single event will create a loop of repeated errors in DNA which will initiate neoplastic transformation.”
BackgroundZhang, Q., Fu, I., Broyde, S. B., & Tretyakova, N. Y. (2025) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5c00215 · Cited by 1
Li, T., Lian, B., Liu, Y., Guo, L., & Li, J. (2026) · Breast Cancer Research · doi:10.1186/s13058-026-02291-y · Cited by 1
“Notably, the differential sensitivity to PARP inhibitors aligns with the expression pattern of MAGEA4, which has been implicated in translesion DNA synthesis and PARP inhibitor resistance [37, 38].”
Exploiting DNA damage tolerance for precision oncology
Bhat, A., Lahane, G. P., PANDITA, R. K., Bacolla, A., Hoden, B., Ramos, K. S., Krishnan, S., Sarkar, P. S., Dhar, A., Tainer, J. A., et al. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.08.003 · Cited by 1
Li, Q. (2021) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.11002
Ma, X., Yang, F., Ma, K., Shen, H., Han, J., Wang, K., Yang, Y., Zhu, J., An, R., Wang, Q., et al. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250241
Wu, J., Xiao, G., Zhao, D., Luo, Y., Li, S., Zhang, Q., & Chen, F. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107221
Drosophila intestinal stem cell response to DNA damage and replication stress
Boumard, B. (2021) · theses.fr (ABES) · doi:10.70675/848566f0z81b5z4b78z9817z58941b02acd2
A p53-dependent FBXO44-RAD18 axis limits mutagenesis by terminating translesion DNA synthesisPreprint
Butera, A., Caporali, S., Capradossi, F., Smith, P., Tabagari, N., Nikoloska, N., Mayans, O. M., Janic, A., Gruber, A. J., D’Angiolella, V., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.27.739831
Ayiku, P. J., Barda, N., Weiss, O. E., Sherman, C., Litvinov, D., Fozailoff, D., Dromi, I., Turgeman, G., & Listovsky, T. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1859193 · Cited by 1
“TLS is an essential DNA damage tolerance mechanism that allows replication to proceed across DNA lesions without repairing the damage itself (Yamanaka et al., 2017; Xie et al., 2010; Chang and Cimprich, 2009).”
Engel, B., Szikriszt, B., Gyüre, Z., Sale, J. E., Szüts, D., & Németh, E. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2526551123
Niedermayer, K., Greco, S., Oechsle, A., Köhler, T., Pantel, K., Friedl, T. W. P., Janni, W., Rack, B., Pfister, K., Gottifredi, V., et al. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03377-4
“TLS inhibitors were proposed as a novel class of adjuvant anti-cancer agents, enhancing cytotoxicity by preventing cancer cell recovery after DNA damage [27, 28].”
DNA Polymerase Eta Stabilizes Mutant p53 Protein to Increase Tumor Cell Growth
Zhang, J., Shi, Y., & Chen, X. (2026) · Cells · doi:10.3390/cells15201881
Metadata
- Authors
- Yamanaka, K., Chatterjee, N., Hemann, M. T., & Walker, G. C.
- Affiliations
- Massachusetts Institute of Technology (US)
- Corresponding author
- Walker, Graham C.
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-08-17
- Volume
- 13
- Issue
- 8
- Pages
- e1006842
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC5560539
- OpenAlex
- W2747521922
- Cited by
- 87
- References
- 120
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 8 · 2023: 12 · 2022: 11 · 2021: 13 · 2020: 12 · 2019: 11 · 2018: 5 · 2017: 1
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- PLoS eBooks
- Funders
- National Institute of Environmental Health Sciences (ES-002109, ES-015818, P30ES002109, R56ES015818, R01ES015818)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- translesion synthesis, chemoresistance, acquired drug resistance, intrinsic drug resistance, Rev1, Y-family DNA polymerases, DNA damage, chemotherapy, adjuvant therapy, protein-protein interfaces
- MeSH terms
- Animals, Antineoplastic Agents, DNA Damage, DNA-Directed DNA Polymerase, DNA Repair, DNA Replication, Humans, Drug Resistance, Neoplasm, Nucleic Acid Synthesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.